← All trials
NCT05604521
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2022
- Primary completion
- Oct 25, 2023
- Completion date
- Oct 25, 2023
- First posted
- Nov 3, 2022
- Last posted
- Nov 4, 2022
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sanaria Inc.Lead sponsor
- University of MarylandCollaborator
- University of MarylandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.